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DOI 10.1016/j.ccr.2012.04.025SUMMARYCancer-associated inflammation is thought to be a barrier to immune surveillance, particularly in pancreatic
ductal adenocarcinoma (PDA). Gr-1+ CD11b+ cells are a key feature of cancer inflammation in PDA, but
remain poorly understood. Using a genetically engineeredmousemodel of PDA, we show that tumor-derived
granulocyte-macrophage colony-stimulating factor (GM-CSF) is necessary and sufficient to drive the devel-
opment of Gr-1+ CD11b+ cells that suppressed antigen-specific T cells. In vivo, abrogation of tumor-derived
GM-CSF inhibited the recruitment of Gr-1+ CD11b+ cells to the tumor microenvironment and blocked tumor
development—a finding that was dependent on CD8+ T cells. In humans, PDA tumor cells prominently ex-
pressedGM-CSF in vivo. Thus, tumor-derivedGM-CSF is an important regulator of inflammation and immune
suppression within the tumor microenvironment.INTRODUCTION
Host inflammatory responses often accompany and even
promote tumor development. Although the prevailing theory of
immunosurveillance holds that the adaptive arm of the immune
system can mount productive anti-tumor responses that elimi-
nate malignant cells (Schreiber et al., 2011), the developing
tumor will often co-opt the host immune system for its own
tumor-promoting purposes. This phenomenon is particularly
notable in the development of pancreatic ductal adenocarci-
noma (PDA), a highly lethal malignancy associated with a striking
desmoplastic reaction and a marked infiltration of leukocytes
into the stromal compartment (Clark et al., 2007). Leukocytes
infiltrating PDA lesions are predominantly derived from the innate
immune system and coordinate a network of local immuneSignificance
PDA carries a dire prognosis for which novel therapeutic stra
stromal reaction is characteristic of PDA and likely contributes
model of PDA, we demonstrate that tumor-derived GM-CSF dr
of the cancer-associated inflammatory reaction, which in turn s
cells prominently expressed GM-CSF in vivo. Our findings s
between tumor cells and the immune system by targeting
differentiation.
822 Cancer Cell 21, 822–835, June 12, 2012 ª2012 Elsevier Inc.suppression (Clark et al., 2007, 2009). Nevertheless, these
immunosuppressive cells exhibit dynamic motility and function,
such that a detailed understanding of inflammatory cellular
mechanisms in this disease has revealed therapeutic targets
that can be translated to clinical success in patients (Beatty
et al., 2011).
Although multiple mechanisms are thought to contribute to
immune suppression in tumor-bearing hosts, tumor-associated
changes in myelopoiesis that result in an abnormal accumulation
of immature myeloid cells in the tumor are thought to play a crit-
ical immunosuppressive role (Gabrilovich and Nagaraj, 2009;
Ostrand-Rosenberg and Sinha, 2009; Peranzoni et al., 2010).
In mice, these immature myeloid cells, often called myeloid-
derived suppressor cells (MDSC), co-express the markers Gr-1
and CD11b and represent a heterogeneous population of cellstegies are urgently needed. An inflammatory desmoplastic
to disease progression. Here, using a spontaneous murine
ives the accumulation of Gr-1+ CD11b+ myeloid cells as part
uppresses antitumor T cell immunity. In humans, PDA tumor
uggest a therapeutic potential for disrupting the crosstalk
Gr-1+ CD11b+ cells or the cytokines that regulate their
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granulocytes at earlier stages of differentiation (Gabrilovich and
Nagaraj, 2009; Ostrand-Rosenberg and Sinha, 2009; Peranzoni
et al., 2010). Normal mouse bone marrow contains 20%–30%
of Gr-1+ CD11b+ cells, although these cells only comprise 2%–
4% of spleen cells and are virtually absent from the lymph nodes
(Gabrilovich and Nagaraj, 2009). Numerous studies have
reported the expansion of Gr-1+ CD11b+ cells in a variety of
implantable tumor models and have demonstrated the ability
of these myeloid cells to impair T cell responses in vitro (Bronte
et al., 2003; Kusmartsev et al., 2004; Sinha et al., 2005). In genet-
ically defined mouse models of cancer—which more closely
recapitulate the tumor microenvironments observed in patients
with the same disease—the role of these cells remains contro-
versial particularly with regard to the in vivo relevance of the
T cell suppressive qualities that are typically demonstrated
in vitro (Andreu et al., 2010; Clark et al., 2007; Melani et al.,
2003; Stairs et al., 2011). Moreover, the soluble factors that drive
the accumulation of Gr-1+ CD11b+ cells in genetically defined
models of cancer, particularly in PDA, remain largely unknown.
To understand the role of Gr-1+ CD11b+ cells in PDA, we
focused on the KPCmouse model of spontaneous PDA in which
expression of oncogenic KrasG12D and mutant p53R172H is tar-
geted to the pancreas by Cre recombinase under the control of
the pancreatic specific promoter Pdx-1 (Hingorani et al., 2005).
This model is fully penetrant with regard to tumor formation,
and KPC mice develop primary PDA lesions that faithfully reca-
pitulate the salient clinical, histopathological, and molecular
features of the human disease, including progression from prein-
vasive pancreatic intraepithelial neoplasia (PanIN) to invasive
cancer to metastatic disease (Hingorani et al., 2005). Using the
KPC model, we evaluate a mechanism of tumor-induced
immune modulation that is critical to maintaining the local
immune suppressive network characteristic of PDA.
RESULTS
The dense desmoplasia and leukocytic infiltration classically
observed in the tumor stroma of patients with PDA is reproduced
with high fidelity in the KPC murine model of the disease (Beatty
et al., 2011; Clark et al., 2009; Hingorani et al., 2005). In tumor-
bearing KPC mice, we found that Gr-1+ CD11b+ cells promi-
nently accumulated in both the tumor and the spleen compared
to normal controls, comprising 20%–30% of all leukocytes in
these tissues (Figure 1A). By immunohistochemistry, Gr-1+
CD11b+ cells were evident in close proximity to tumor cells (Fig-
ure 1B). Gr-1+ CD11b+ cells were also prominently associated
with metastatic lesions in this model, but were not found in other
tissues that lacked metastases (Figure 1C). Sorted Gr-1+
CD11b+ leukocytes from the spleen or tumor of KPC mice
comprised a heterogeneous population of myeloid cells
including myelocytes, metamyelocytes, band and segmented
neutrophils, and monocytoid cells (Figure 1D), consistent with
previous observations of cancer-associated Gr-1+ CD11b+ cells
(Andreu et al., 2010; Bronte et al., 2000; Stairs et al., 2011).
Various terms have been used in the literature to describe
Gr-1+ CD11b+ cells, including immature myeloid cells (Kusmart-
sev and Gabrilovich, 2006) or myeloid derived suppressor cells
(MDSC) (Gabrilovich et al., 2007). Because the latter termsuggests that Gr-1+ CD11b+ cells act to suppress T cell activa-
tion, we sought to understand the potential immunosuppressive
function of Gr-1+ CD11b+ cells in the KPC model. We therefore
evaluated the capacity of highly enriched or sorted Gr-1+
CD11b+ cells from tumor-bearingmice to suppress in vitro prolif-
eration of ovalbumin-specific CD8+ T cells from OT-1 transgenic
mice in response to cognate peptide antigen. We found that
Gr-1+ CD11b+ cells isolated from either the spleen or pancreas
of tumor-bearing KPC mice potently suppressed proliferation
(Figure 2A; Figure S1 available online) as well as interferon-
gamma (IFN-g) production by OT-1 cells (Figure 2B). Gr-1+
CD11b+ cells from tumor-bearing KPC mice also suppressed
the proliferation of splenic T cells from normal mice stimulated
polyclonally with anti-CD3 plus anti-CD28 antibodies (Figure S1).
Moreover, Gr-1+ CD11b+ cells exhibited high levels of arginase
activity (Figure 2C) and produced high levels of nitrite upon
culture (Figure 2D), suggesting expression of inducible nitric
oxide synthase (iNOS); both arginase and iNOS have been previ-
ously linked to immunosuppression by Gr-1+ CD11b+ cells in
tumor-bearing mice (Bronte and Zanovello, 2005; Ma et al.,
2011). We found that inhibition of iNOS and, to a lesser extent,
arginase abrogated the capacity of Gr-1+ CD11b+ cells to
suppress T cell proliferation (Figure 2E). This set of properties
of Gr-1+ CD11b+ cells in KPC mice is consistent with described
properties of MDSC (Gabrilovich et al., 2007).
We then examined the potential origin of Gr-1+ CD11b+ cells.
We noted that unlike normal controls, tumor-bearing KPC mice
developed splenomegaly as a result of extramedullary hemato-
poiesis (Figures 3A and 3B) and concomitant to accumulation
of Gr-1+ CD11b+ cells in the spleen (Figure 1A). Splenocytes
from tumor-bearing KPC mice exhibited a distinct c-kit+ popula-
tion, higher in percentage than found in splenocytes from normal
mice and similar to the percentage of c-kit+ precursors found in
bone marrow (Figure 3B). Given the link between the tumor
microenvironment and accumulation of functional Gr-1+
CD11b+ cells in the KPC model, we hypothesized that a tumor-
derived factor might drive the generation of Gr-1+ CD11b+ cells
from c-kit+ cells in the spleen. We therefore isolated c-kit+
Gr-1 CD11b lineage cells from the spleens of tumor-bearing
KPC mice and incubated them with conditioned media obtained
from cultured PDA tumor cells that had been previously isolated.
Conditioned media from tumor cells, but not control media,
triggered proliferation of c-kit+ splenocytes, as evidenced by
carboxyfluorescein diacetate succinimidyl ester (CFSE) dilution
(Figure 3C) or bromodeoxyuridine (BrdU) incorporation (Fig-
ure S2). In contrast, Gr-1+ CD11b+ splenocytes isolated from
the samemice did not proliferate in response to tumor cell condi-
tioned media (Figure 3C). Importantly, after 5 days of co-culture,
c-kit+ cells expressed high levels of Gr-1 and CD11b (Figure 3C),
exhibited arginase and iNOS activity (Figure 3D), and potently
suppressed T cell proliferation in the OT-1 T cell suppression
assay (Figure 3E).
To identify tumor-derived soluble factors contributing to the
generation of Gr-1+ CD11b+ cells from c-kit+ precursors, we
measured a set of secreted proteins in conditioned media from
a panel of PDA tumor cell lines and compared the results to those
for conditioned media from benign pancreatic ductal cells from
normal control mice. Conditioned media from every PDA line
supported proliferation of c-kit+ cells into Gr-1+ CD11b+ cellsCancer Cell 21, 822–835, June 12, 2012 ª2012 Elsevier Inc. 823
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Figure 1. Gr-1+ CD11b+ Cells Accumulate in the Spleen and Tumor of PDA-Bearing KPC Mice
(A) Gr-1+ CD11b+ cells from the spleen and pancreas of tumor-bearing KPC mice versus normal control mice were evaluated by flow cytometry. Representative
flow plots for onemouse in each category (left) and summary data (right) are shown. Cells were gated for CD45 expression and then analyzed. Numbers in top right
corner of the plots represent the percentage of Gr-1+ CD11b+ cells among total CD45+ cells. For summary data, each symbol represents an individual mouse:
spleen (light gray), pancreas (dark gray), normal mice (triangles) and PDA mice (diamonds). Black horizontal bars represent the mean for each group (n = 10
for normal spleen, n = 15 for PDA spleen, n = 3 for normal pancreas, and n = 13 for PDA pancreas). Nml, normal. ***p < 0.001 for the comparisons shown.
(B) H&E stain (left) and immunohistochemistry for CD45 (middle) or Gr-1 (right) on a representative PDA lesion. Scale bars, 50 mM.Highermagnification images are
shown in the top right corner of each panel.
(C) Metastatic lesions on the liver and diaphragm of a representative KPCmouse were evaluated by flow cytometry for Gr-1+ CD11b+ cells (after gating for CD45
expression), compared to salivary gland cells as a control.
(D) Diff-Quick stain of cytospin preparation of sorted CD45+ Gr-1+ CD11b+ cells from the spleen of a tumor-bearing KPC mouse. Scale bar, 20 mM.
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Figure 2. Gr-1+ CD11b+ Cells Isolated
from Tumor-Bearing KPC Mice Suppress
Antigen-Specific T Cell Responses In Vitro
(A) Gr-1+ CD11b+ cells isolated from either the
spleen (light gray bars) or pancreas (dark gray
bars) of tumor-bearing KPC mice were cocultured
with peptide-stimulated OT-1 splenocytes and
proliferation was evaluated by 3[H]-thymidine
incorporation. Assay was performed in triplicate;
data are mean ± SD, representative of 5–10 inde-
pendent experiments. **p < 0.01, ***p < 0.001,
compared to OT-1 alone.
(B) IFN-g in supernatant from co-culture of Gr-1+
CD11b+ cells with OT-1 splenocytes (1:1 ratio) was
measured by cytokine bead array. Data are
representative of two independent experiments.
(C) Arginase activity was evaluated in the Gr-1+
fraction of normal spleens and tumor-bearing KPC
spleens. Assay was performed in triplicate; data
are mean ± SD, representative of two independent
experiments. *** indicates p < 0.001.
(D) Nitrite concentration in supernatant from
coculture of Gr-1+ CD11b+ cells with OT-1 sple-
nocytes (1:1 ratio) was measured by the Griess
reaction as an indicator of iNOS activity. Data are
mean ± SD, representative of 3 independent
experiments. *** indicates p < 0.001.
(E) Small molecule inhibition of iNOS relieves
antigen-specific suppression of T cell proliferation
mediated by Gr-1+ CD11b+ cells. Proliferation
assay was performed in triplicate at 1:1 ratio of
Gr-1+ CD11b+ cells to OT-1 cells; data are
mean ± SD nor-NOHA (arginase inhibitor), Nu-
hydroxy-nor-L-arginine; L-NMMA (iNOS inhibitor),
NG-monomethyl-L-arginine. **p < 0.01, compared
to OT-1 alone.
See also Figure S1.
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supported c-kit+ cell proliferation (Figure 4A). Among 11 proteins
examined, only granulocyte-macrophage colony-stimulating
factor (GM-CSF) was expressed at high levels by every PDA
line but not by any of the normal pancreatic ductal lines (Fig-
ure 4A), suggesting that tumor-derived GM-CSF might be linked
to Gr-1+ CD11b+ cell generation. We therefore tested recombi-
nant GM-CSF in our in vitro assays and found that GM-CSF
drove proliferation and differentiation of c-kit+ Gr-1 CD11b
splenocytes isolated from tumor-bearing mice into functional
MDSC (Figure 4B). Proliferation and differentiation of c-kit+
Gr-1 CD11b splenocytes was not observed with recombinant
vascular endothelial cell growth factor (VEGF) or stem cell factor
(SCF, also known as c-kit ligand) and only minimally withCancer Cell 21, 822–8interleukin-6 (IL-6) (Figure S3). Interme-
diate proliferation was observed with
only high concentrations of recombinant
macrophage colony-stimulating factor
(M-CSF). In each case, neutralization of
GM-CSF in tumor cell conditioned media
by the addition of anti-GM-CSF mAb
completely abrogated generation of
Gr-1+ CD11b+ cells from c-kit+ precur-
sors (Figure 4C and Figure S3). Neutral-izing antibodies to other cytokines such as anti-SCF, anti-IL-6,
or anti-interleukin-1b (IL-1b) had no effect (Figure S3), suggest-
ing that GM-CSF is both necessary and sufficient for in vitro
generation of functional, immunosuppressive Gr-1+ CD11b+
cells.
To understand the relevanceof tumor-derivedGM-CSF in vivo,
first we isolated fresh pancreatic tissue from tumor-bearing KPC
mice versus normal controls and measured GM-CSF concentra-
tions in tissue supernatant. Higher amounts of GM-CSF (>1 log)
per gram of tissue were detected in pancreata from tumor-
bearing KPC mice relative to pancreata from normal mice (Fig-
ure 5A). (Chemokines KC and CCL2 were also elevated in tumor
tissue, consistent with the cell line cytokine data.) To determine
which cells produce GM-CSF within tumors from genetically35, June 12, 2012 ª2012 Elsevier Inc. 825
Figure 3. c-kit+ Lineage– Splenocytes Are Highly Proliferative Precursors of Gr-1+ CD11b+ Cells and Are Driven to Proliferate via Tumor-
Derived Factors
(A) Tumor-bearing KPCmice exhibit splenomegaly as indicated by spleen size of normal mice and tumor-bearing KPCmice (left) and spleen weight of normal and
KPC mice (right). Black horizontal bars represent the mean for each group (n = 5 for normal mice, n = 12 for KPC mice). Nml, normal. **p < 0.01.
(B) H&E of tumor-bearing KPC spleen (left) reveals marked disruption of normal splenic architecture and classic findings of extramedullary hematopoiesis. Note
the abundance of megakaryocytes (white arrow) and areas of erythropoiesis (black arrow). Scale bars, 50 mM. Spleen and bone marrow from normal and tumor-
bearing KPC mice (right) were evaluated by flow cytometry for c-kit+ cells.
(C) c-kit+ Gr-1 CD11b cells (top) and Gr-1+ CD11b+ cells (bottom) from the spleens of tumor-bearing KPC mice were labeled with CFSE and cultured in the
presence of either unconditioned control media (No CM) or PDA conditioned culture media from KPC tumor lines (+ CM). Gr-1+ CD11b+ phenotype is shown at
baseline post-isolation (left). Flow cytometric analysis of CFSE dilution on day 5 (middle) demonstrates that Gr-1 CD11b c-kit+ cells proliferate in response to
tumor conditioned media, but not control media, whereas freshly isolated Gr-1+ CD11b+ MDSC do not proliferate in either condition. Black horizontal bars
indicate undiluted CFSE intensity on day 5. The day 5 output of the proliferative Gr-1 CD11b c-kit+ culture was evaluated by flow cytometry for surface
expression of Gr-1 and CD11b (far right). Data are representative of 5–10 independent experiments.
(D) The Gr-1+ CD11b+ cells generated from c-kit+ cells after 5 days with CM were evaluated for arginase (left) and iNOS (right) activity. Data are mean ± SD from
one of two independent experiments; **p < 0.01, ***p < 0.001.
(E) Suppressive capacity of the Gr-1+ CD11b+ cells generated from c-kit+ cells after 5 days with CM was assessed in the OT-1 T cell suppression assay, per-
formed in triplicate. Data are mean ± SD. **p < 0.01, ***p < 0.001, compared to OT-1 alone.
See also Figure S2.
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ure 5B). A conditional Rosa26-Lox-STOP-Lox-YFP (RosaYFP)
allele was bred onto the KrasG12D; p53fl/+; Pdx-1-Cre back-
ground to permanently label the pancreatic epithelial compart-
ment during embryonic development. This approach led to
sensitive (>95% of all pancreatic epithelial cells) and specific
labeling of pancreas epithelial-derived cells, with no stromal cells
labeled (Rhim et al., 2012). Tumors from these mice and normal
pancreata from lineage labeled wild-type mice (Pdx-1-Cre;
RosaYFP) were harvested, dissociated, and single cells were
directly sorted based on YFP fluorescence. Subsequent tran-
scriptional analysis revealed that YFP+ cells from tumor-bearing826 Cancer Cell 21, 822–835, June 12, 2012 ª2012 Elsevier Inc.mice expressed high levels of GM-CSF mRNA compared to
YFP cells from the same mice (Figure 5B). GM-CSF mRNA
was undetectable in either YFP+ or YFP cells from control
mice. To investigate GM-CSF expression by human tumors
in vivo, we performed immunohistochemistry for GM-CSF on
20 PDA tumor samples obtained from patients who had under-
gone surgical resection of a primary PDA tumor. In 19 of these
cases, tumor cells prominently expressed GM-CSF (>50% of
tumor cells positive) (Figure 5C). For the positive samples, the
percentage of tumor cells that expressed GM-CSF was
84.2% ± 13.8% (mean ± SD). Tumor cells that lacked GM-CSF
expression were observed scattered throughout the tumor
Figure 4. Tumor-Derived GM-CSF Induces Proliferation and Differentiation of c-kit+ Lineage– Precursors into Functional MDSC
(A) Cytokines produced by primary PDA lines derived from KPC tumors and normal pancreatic ductal cell lines are compared in a heat map. Color scale and
corresponding cytokine values (pg/ml) are shown below. Last column indicates whether conditioned media from that cell line was found to drive proliferation of
c-kit+ lineage cells in a CFSE proliferation assay. Nml, normal; nd, not determined.
(B) Recombinant GM-CSF is sufficient to induce proliferation and differentiation of c-kit+ lineage cells into MDSC. Day 5 FACS analysis (left) was performed
to evaluate Gr-1 and CD11b expression on c-kit+ lineage splenocytes cultured with control media (No CM), CM from PDA lines (+ PDA CM), or recombinant
GM-CSF (200 pg/ml). Suppressive capacity of culture outputs (right) was evaluated in the OT-1 T cell suppression assay. Data are representative of at least three
independent experiments.
(C) CFSE dilution of c-kit+ lineage cultures is shown for day 5. Neutralization of GM-CSF by anti-GM-CSF mAb (100 mg/ml) in PDA-1 conditioned media blocks
proliferation of c-kit+ lineage cells. Black horizontal bars indicate undiluted CFSE intensity on day 5. Data are representative of independent experiments using
conditioned media from 3 different PDA cell lines. As a control, the neutralizing capability of this anti-GM-CSF mAb was shown by its effect on recombinant
GM-CSF in this assay.
See also Figure S3.
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Figure 5. PDA Cells Produce GM-CSF and Other Factors In Vivo in KPC Mice
(A) Cytokines in fresh PDA supernatant (directly ex vivo) versus normal pancreas supernatant were compared by cytokine bead array. y-Axes are on log scales;
each symbol represents an individualmouse: normal mice (light gray diamonds) and PDAmice (dark gray diamonds). Black horizontal bars represent themean for
each group (n = 3 for normal mice, n = 7 for PDA mice). **p < 0.01.
(B) Transcriptional analysis was used to evaluate GM-CSFmRNA expression of YFP+ (epithelial) cells versus YFP (stromal) cells sorted from tumors of KrasG12D;
p53fl/+; Pdx-1-Cre; RosaYFPmice (n = 3) or normal pancreata from lineage labeled wild-type mice (Pdx-1-Cre; RosaYFP) (n = 3). Data are mean ± SD. *p < 0.05,
***p < 0.001.
(C) Immunohistochemistry for GM-CSF was performed on surgical pancreas samples from 20 patients with PDA. PDA tumors from three representative patients
are shown (upper left, upper right, lower left), and adjacent pancreatic tissue without invasive tumor is shown for one patient (lower right). The lower left panel is
shown at higher power magnification. Scale bars, 50 mM.
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ally found as clusters of cells.
We then studied the role of GM-CSF on tumor growth and
inflammation in vivo. PDA tumor cells that secreted GM-CSF
(cell line PDA-1) were injected subcutaneously in a matrigel
plug containing neutralizing anti-GM-CSF mAb (versus purified
rat IgG2a as a control) into the flanks of normal control mice.
This matrigel subcutaneous assay was developed to allow for
GM-CSF neutralization within the local tumor microenvironment
given that systemic administration of anti-GM-CSF antibody was
unable to achieve sufficient concentrations within the tumor
microenvironment to neutralize GM-CSF effectively (data not
shown). Six days after implantation, PDA-1 cells injected with
IgG2a established tumors, but PDA-1 cells injected with anti-
GM-CSF failed to grow and the injected plugs, upon resection,
weighed statistically significantly less (Figure 6A). Histologically,
PDA-1 cells injected with anti-GM-CSF mAb appeared necrotic
after 6 days compared to viable tumor cell nests in the control828 Cancer Cell 21, 822–835, June 12, 2012 ª2012 Elsevier Inc.(Figure 6A). Moreover, the infiltration of CD45+ Gr-1+ CD11b+
cells observed in control tumors was reduced in tumor cells
implanted with anti-GM-CSF mAb (Figures 6B and 6C). Weight,
histology, and leukocyte infiltration on day 6 was the same for
PDA-1 cells injected with anti-GM-CSFmAb as for lethally irradi-
ated (10 Gy) PDA-1 cells injected with anti-GM-CSF mAb
(Figures 6A and 6C).
To determine whether the GM-CSF that was required for
tumor formation in this assay was tumor-derived, we knocked
down GM-CSF expression in PDA-1 cells using short-hairpin
RNA (shRNA) technology. Compared to vector only (mock
PDA-1 cells), shGM-CSF PDA-1 cells expressed > 90% less
GM-CSF, whereas expression of other cytokines such as
VEGF and KC was not affected (Figure S5). shGM-CSF
PDA-1 cells or mock PDA-1 cells were then implanted subcuta-
neously in matrigel into the flanks of normal control mice and
observed for 6 days. Similar to the experiments with anti-
GM-CSF, mock PDA-1 cells established tumors in vivo, but
Figure 6. GM-CSF Neutralization with Anti-GM-CSF Antibody Limits Tumor Growth and Recruitment of Gr-1+ CD11b+ Cells In Vivo
(A) Normal control mice (6–14 weeks) were implanted subcutaneously with the GM-CSF-producing cell line PDA-1 in matrigel with either a neutralizing anti-GM-
CSF mAb (aGM) or isotype control antibody, with or without tumor cell irradiation (IR), and with or without intraperitoneal administration of a depleting CD8 mAb.
On day 6, tumor growth was evaluated by H&E (top; images of one representative mouse per group are shown) and tumor weight (bottom; data are mean ± SD).
n = 3–11 mice per group. Scale bars, 50 mM. **p < 0.01, ***p < 0.001.
(B) The immune infiltrate was evaluated by immunohistochemistry (left) and immunofluorescence (right) for CD45 and Gr-1. Images of one representative mouse
per group are shown (3–11 mice per group). Scale bars, 50 mM.
(C) Absolute numbers of CD45+ cells (left) andGr-1+ CD11b+ cells (right) were quantified by flow cytometry. Data aremean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001.
See also Figure S4.
Cancer Cell
Tumor GM-CSF and Myeloid Cells in Pancreas CancershGM-CSF PDA-1 cells failed to grow and the resected plugs
weighed significantly less (Figure 7A). Histologically, shGM-
CSF PDA-1 cells appeared necrotic after 6 days compared to
viable tumor cell nests in the control (Figure 7A). There was
a significant reduction in the inflammatory infiltrate in experi-
ments with shGM-CSF PDA-1 cells, including fewer Gr-1+
CD11b+ cells (Figures 7B and 7C). Weight, histology, and leuko-
cyte infiltration on day 6 was the same for shGM-CSF PDA-1
cells as these parameters were for lethally irradiated (10 Gy)
shGM-CSF PDA-1 cells (Figures 7A and 7C).
We also examined the effect of GM-CSF blockade and
knockdown on Gr-1 CD11b+ monocytes/macrophages in the
implanted tumor model. In each experimental system (i.e., anti-
GM-CSF antibody or shGM-CSF), we observed a statistically
significant decrease in tumor infiltrating Gr-1 CD11b+ cells
compared to control tumors (Figure S4). Importantly, a major
subset of Gr-1+ CD11b+ cells were found to express high levels
of Ly6C, and among this population, > 90% expressed the
macrophage marker F4/80 (data not shown), underscoring
a potential biological continuum of monocytes, macrophages,
and immature myeloid cells. We were unable to identify an
adequate method of depleting macrophages without impacting
Gr-1+ CD11b+ cells in our mice. For example, we found that
administration of clodronate encapsulated liposomes (CEL)depleted Gr-1 CD11b+ F4/80+ macrophages as well as
Ly6Chigh Gr-1+ CD11b+ cells (data not shown). We therefore
repeated our tumor implantation experiments with anti-Gr-1
antibody versus isotype control and found that administration
of anti-Gr-1 antibody depletes Gr-1+ CD11b+ myeloid cells but
not Gr-1 CD11b+ macrophages (Figure S4). Importantly, coin-
jection of anti-Gr-1 antibody with PDA-1 cells recapitulated our
findings with anti-GM-CSF such that tumor implants failed to
grow (Figure S4). Thus, depletion of Gr-1+ CD11b+ cells alone
is sufficient for impaired tumor growth in this model.
We hypothesized that GM-CSF produced by tumor cells may
drive the generation of Gr-1+ CD11b+ cells, which suppress anti-
tumor T cell immunity. We therefore examined whether tumor
rejection observed in the setting of GM-CSF neutralization or
genetic knockdown was mediated by CD8+ T cells. We repeated
the 6 day implantation experiments in the setting of in vivo
CD8 depletion (Figure S4). Strikingly, CD8 depletion restored
tumor growth for both PDA-1 cells implanted with anti-GM-
CSF and shGM-CSF PDA-1 cells (Figures 6A and 7A), linking
tumor-derived GM-CSF to Gr-1+ CD11b+ cell accumulation
and CD8+ T cell suppression. To confirm this, we used a genetic
approach and repeated experiments in Rag2/ mice. We
found that shGM-CSF PDA-1 tumor cells grew vigorously in
Rag2/ mice, even though they failed to grow in T cell repleteCancer Cell 21, 822–835, June 12, 2012 ª2012 Elsevier Inc. 829
Figure 7. Genetic Knockdown of GM-CSF Demonstrates that Tumor-Derived GM-CSF Regulates Tumor Growth and Recruitment of Gr-1+
CD11b+ Cells In Vivo
(A) Normal control mice or Rag2/ mice (6–14 weeks) were implanted subcutaneously with either shGM-CSF PDA-1 cells (shGM) or vector only PDA-1 cells
(Mock) inmatrigel with or without tumor cell irradiation (IR), andwith or without intraperitoneal administration of a depleting CD8mAb. On day 6, tumor growthwas
evaluated by H&E (top; images of one representative mouse per group are shown) and tumor weight (bottom; data are mean ± SD). n = 3 to 7 mice per group.
Scale bars, 50 mM. *p < 0.05, **p < 0.01, ***p < 0.001.
(B) The immune infiltrate was evaluated by immunohistochemistry (left) and immunofluorescence (right) for CD45 and Gr-1. Images of one representative mouse
per group are shown (3–7 mice per group). Scale bars, 50 mM.
(C) Absolute numbers of CD45+ cells (left) andGr-1+ CD11b+ cells (right) were quantified by flow cytometry. Data aremean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001.
See also Figure S5.
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trated tumors more vigorously after GM-CSF knockdown. This
finding was demonstrated by immunofluorescence for CD8
expression and quantified by flow cytometry (Figure S5). To
understand if CD8+ T cells from GM-CSF knockdown tumors
exhibited effector functions, we evaluated tumor-infiltrating
CD8+ T cells for their capacity to secrete IFN-g and mobilize
CD107a, the latter serving as a biomarker of lytic function
(Betts et al., 2003). We found that compared to CD8+ T cells
from mock PDA-1 tumors, CD8+ T cells from shGM-CSF
PDA-1 tumors exhibited a higher percentage of IFN-g+ CD107a+
cells (Figure S5). Importantly, CD8 depletion did not rescue
infiltration of Gr-1+ CD11b+ cells into shGM-CSF PDA-1 tumors,
suggesting that PDA-1 tumor cells can grow in the setting of
minimal Gr-1+ CD11b+ cells, provided CD8+ T cells are absent
(Figure 7).830 Cancer Cell 21, 822–835, June 12, 2012 ª2012 Elsevier Inc.DISCUSSION
It has become widely appreciated that tumor-associated inflam-
mation is an enabling characteristic of cancer and contributes
to tumor escape from immune destruction (Hanahan and
Weinberg, 2011). Here, focusing on PDA in mice as a model of
the human disease, we demonstrate that tumor cell-derived
GM-CSF can orchestrate an immunosuppressive crosstalk
between Gr-1+ CD11b+ immature myeloid cells and CD8+
T cells. Overall, our data support a model in which myeloid
inflammatory cells negatively regulate CD8+ T cells via tumor-
derived GM-CSF (Figure 8).
Although GM-CSF clearly regulates hematopoiesis as
a growth factor, its role as an immunomodulatory cytokine has
become increasingly appreciated. Depending on the setting,
these effects can either promote or suppress cellular immune
GM-CSF
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+
T 
cells
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Figure 8. Working Model Links Tumor-Derived GM-CSF, MDSC
Generation, and CD8+ T Cell Suppression in PDA
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been linked to the generation of Gr-1+ CD11b+ cells with immu-
nosuppressive features (Bronte et al., 1999; Dolcetti et al., 2010;
Morales et al., 2010; Serafini et al., 2004). For example, GM-
CSF-transducedmelanoma cells induce the systemic expansion
of Gr-1+ CD11b+ cells and inhibit memory CD8+ T cells (Bronte
et al., 1999). Knockdown of GM-CSF in tumor cell lines has
been shown to alter the subset distribution of Gr-1+ CD11b+
myeloid cells following implantation in mice, primarily reducing
the Gr-1low and Gr-1int populations which are the most suppres-
sive in these models (Dolcetti et al., 2010). Here, we show that
GM-CSF is produced in vivo in a spontaneous tumor that is char-
acterized by prominent infiltration of suppressive Gr-1+ CD11b+
cells. We also demonstrate that human pancreatic tumors cells
express GM-CSF in vivo; therefore, these findings are signifi-
cantly relevant to understanding the human disease.
GM-CSF may not be critical for the development of Gr-1+
CD11b+ cells in every tumor model or histology. In mice with
combined loss of IFN-g, IL-3, and GM-CSF, lung carcinomas
develop at a high frequency and exhibit an infiltrate of Gr-1+
CD11b+ leukocytes (Dougan et al., 2011). Moreover, cytokines
and growth factors other than GM-CSF have been implicated
in the pathophysiology of Gr-1+ CD11b+ leukocytes in other
mouse models—including IL-1b, IL-6, and VEGF (Melani et al.,
2003)—but none of these factors explains the effects we
observed regarding the generation of suppressive Gr-1+
CD11b+ cells in the PDA model. For example, the pro-inflamma-
tory cytokine IL-1b has been implicated in MDSC pathophysi-
ology such that fibrosarcoma or 4T1 mammary carcinoma cell
lines engineered to secrete IL-1b grow more rapidly than control
tumors upon implantation due to enhanced accumulation of
Gr-1+ CD11b+ and concomitant T cell suppression (Bunt et al.,
2006; Song et al., 2005). Mice lacking the IL-1 receptor exhibit
delayed accumulation of MDSC and slower progression of
implanted 4T1 mammary tumors and interestingly, these effects
are partially restored by exogenous administration of IL-6,
indicating that IL-6 may contribute independently to MDSC
expansion (Bunt et al., 2007). Stomach-specific expression of
human IL-1b in transgenic mice leads to spontaneous gastric
inflammation, invasive cancer, and mobilization of MDSC (Tu
et al., 2008). In the KPC model of PDA, however, we observed
accumulation of Gr-1+ CD11b+ cells in the spleen and tumor
despite the observations that (1) PDA tumor cells did not secreteIL-1b, and (2) the addition of neutralizing anti-IL-1b antibody to
PDA-conditioned media failed to attenuate the proliferation
and induction of MDSC from precursor cells. Although recombi-
nant IL-6 did trigger low level proliferation of c-kit+ splenocytes,
PDA tumors cells (with one exception) did not produce IL-6 and
the addition of neutralizing anti-IL-6 antibody to PDA-condi-
tioned media had no effect in these assays. More likely in PDA,
tumor-associated macrophages release IL-6 that directly affects
the epithelium and promotes PanIN progression and PDA devel-
opment in vivo (Beatty et al., 2011; Lesina et al., 2011). Indeed,
our data are consistent with those of previous studies demon-
strating IL-6 production primarily by stromal cells, not the tumor,
in mouse models (Lesina et al., 2011) as well as human PDA
(Bellone et al., 2006; Lesina et al., 2011). In mice, IL-6 production
can be induced in PDA tumor cells, or in pancreas epithelium
harboring mutant Kras, but only after an acute inflammatory
insult (Fukuda et al., 2011). IL-6 production has been reported
in some, but not all, human PDA cell lines (e.g., Bellone et al.,
2006). In addition, IL-6 expression in tumors may be silenced
by DNA methylation (Dandrea et al., 2009). For IL-1b, variable
expression by human PDA cell lines has been described (Bellone
et al., 2006), and in mice, IL-1b can be induced in pancreas
epithelium harboring mutant Kras, but only after an acute inflam-
matory insult (Fukuda et al., 2011). Overexpression of IL-1b in the
mouse pancreas results in pancreatitis but interestingly, not
PanIN or PDA (Marrache et al., 2008).
To understand whether GM-CSF production is an early event
in oncogenesis, we generated PanIN epithelial cell lines from
PanIN-only-bearing KPC mice and found low level production
of GM-CSF. Supernatant from PanIN lines supported the prolif-
eration of c-kit+ splenocytes into Gr-1+ CD11b+ cells, but not to
the extent of supernatant from PDA lines (data not shown). This
proliferation, however, could be fully blocked by anti-GM-CSF
antibody. A caveat from our studies is that we cannot determine
the grade of the PanIN lesions fromwhich the lines were derived.
Importantly, our results are consistent with data described by
Pylayeva-Gupta et al. (Pylayeva-Gupta et al., 2012).
VEGF and granulocyte colony-stimulating factor (G-CSF) have
also been implicated in MDSC development (Gabrilovich et al.,
1998; Huang et al., 2007; Roland et al., 2009; Dolcetti et al.,
2010). In our model of PDA, however, recombinant VEGF had
little or no effect on the generation of Gr-1+ CD11b+myeloid cells
from precursor cells isolated from PDA-bearing KPC mice even
though our PDA lines produce high levels of VEGF. Furthermore,
normal pancreatic ductal cells also secreted VEGF (albeit some-
what less so than PDA cells) yet Gr-1+ CD11b+ cells did not
accumulate around normal ducts in vivo and conditioned media
from normal ductal cells failed to support proliferation of c-kit+
splenocytes intoMDSC.We found thatmost PDA lines produced
G-CSF; however, supernatant from a G-CSF negative line sup-
ported proliferation of c-kit+ splenocytes. Some of the normal
ductal cell lines also produced G-CSF yet supernatant from
these normal lines did not support c-kit+ cell expansion.
Recent studies have also linked the chemokine CCL21 to the
appearance ofMDSC in the B16-F10 implantablemodel of mela-
noma (Shields et al., 2010), and other investigators have uncov-
ered that IL-25 elicits a multipotent progenitor cell population in
mucosal tissue that can differentiate into cells of various myeloid
lineages (Saenz et al., 2010), but neither CCL21 nor IL-25 isCancer Cell 21, 822–835, June 12, 2012 ª2012 Elsevier Inc. 831
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high levels of CCL2 and KC, we also evaluated these factors in
our in vitro assays, but neither supported the proliferation of
precursors into MDSC, and moreover, these factors were
produced by normal pancreatic epithelial cells. Rather, GM-CSF
was the only factor that met all the criteria of a tumor-associated
driving factor for MDSC generation in our experimental system
(i.e., secreted by PDA, not secreted by normal pancreatic epithe-
lial cells, and contributed necessarily to the generation of
suppressive MDSC from c-kit+ splenocytes).
Disruption of CD8 immunity by elements of the tumormicroen-
vironment is thought to be a major mechanism of tumor immune
escape (Schreiber et al., 2011). Our data demonstrate the critical
role Gr-1+ CD11b+ cells play in suppressing T cell immune
responses in vitro and in vivo in PDA. In particular, abrogation
of tumor-derived GM-CSF reduced Gr-1+ CD11b+ cell infiltration
and implanted tumors failed to grow; however, CD8+ T cell
depletion fully rescued tumor growth, even though Gr-1+
CD11b+ cell infiltration was not completely restored. These
data suggest that Gr-1+ CD11b+ cells can play a primary immune
suppressive role. Other potential roles of Gr-1+ CD11b+ cells in
regulating tumor growth (Yang et al., 2004, 2008, 2011) appear
therefore to be secondary or noncontributory to tumor growth,
at least in this assay. This may explain our previous observation
that in genetically engineered murine models of PDA, the infiltra-
tion of CD8+ T cells and Gr-1+ CD11b+ cells is mutually exclu-
sive (Clark et al., 2007).
In summary, we propose that the secretion of GM-CSF by
transformed pancreatic epithelial cells is critically involved in
the regulation of inflammation associated with PDA. A major
component of this inflammation is the generation of Gr-1+
CD11b+ immature myeloid cells from c-kit+ lineage precursor
cells. We show that these myeloid cells can suppress antitumor
T cell immunity as a primary function and suggest that MDSC
contribute to the failure of T cell immunosurveillance in PDA-
bearing hosts. In patients, nearly every tumor studied had high
GM-CSF expression so that it was not practical to correlate
levels of tumor GM-CSF with Kras mutational status. Our find-
ings carry important implications for the design of novel
therapies for patients with PDA and highlight the potential for dis-
rupting the crosstalk of tumor cells with the immune system by
targeting Gr-1+ CD11b+ cells or the cytokines that regulate their
differentiation.
EXPERIMENTAL PROCEDURES
Mice
All animal protocols were reviewed and approved by the Institutional Animal
Care and Use Committee of the University of Pennsylvania. KrasLSL-G12D/+,
Trp53LSL-R172H/+, Pdx1-Cre (KPC) mice have been previously described
(Hingorani et al., 2005). Normal healthy Trp53LSL-R172H/+, Pdx1-Cre mice or
Pdx1-Cre mice were used as controls or hosts for implantable tumor studies.
Rag2/ mice were used as hosts in some implantable tumor studies.
KrasG12D; p53fl/+; Pdx1-Cre; RosaYFP and Pdx1-Cre; RosaYFP mice (Rhim
et al., 2012) were used for lineage tracing studies.
Collection of Tissue Samples from Mice
The entire pancreas containing tumor, peripancreatic lymph nodes, and
normal pancreas tissue was washed in PBS, minced into small fragments,
and incubated in collagenase solution (1 mg/ml collagenase V in RPMI-
1640) at 37C for 45 min. Dissociated cells were passed through a 70 mM832 Cancer Cell 21, 822–835, June 12, 2012 ª2012 Elsevier Inc.cell strainer and washed three times in RPMI-1640 supplemented with 10%
FCS and 0.05 mM 2-mercaptoethanol, gentamicin and L-glutamine (complete
media). Spleens were homogenized and passed through a 70 mM cell strainer
to achieve single cell suspensions. Red blood cells were lysed using ACK Lysis
Buffer (Cambrex/BioWhittaker).
Antibodies
The following monoclonal antibodies were used in flow cytometry: anti-CD45
(30-F11; PE, PE-Cy7, APC), anti-Gr-1 (RB6-8C5; APC-Cy7), anti-CD11b (M1/
70; PE, PerCP-Cy5.5), anti-CD3 (145-2C11; FITC), anti-CD8 (Ly-2; PE-Cy7,
APC-Cy7), anti-CD4 (RM4-5; PerCP-Cy5.5), anti-CD19 (1D3; PerCP-Cy5.5),
CD107a (1D4B; FITC), IFN-g (XMG1.2; PE) (all from BD Biosciences), and
anti-CD11c (eBioscience; N418; PerCP-Cy5.5). The viability marker 7-amino-
actinomycin D (7-AAD) was from BD Biosciences. For in vivo studies,
endotoxin-free antibodies were used: anti-GM-CSF (Biolegend; MP1-22E9),
anti-CD8 (BioXcell; 2.43), anti-Gr-1 (BioXcell; RB6-8C5), isotype control rat
IgG2a (BioXcell; 2A3), and isotype control rat IgG2b (BioXcell; LTF-2).
Flow Cytometry
Single cell suspensions were stained with fluorochrome-labeled antibodies at
4C for 15 min in PBS/1% FCS. Cells were analyzed on a FACSCanto flow
cytometer (BD Biosciences) using BD FACSDiva software (BD Biosciences
Immunocytochemistry).
Cytology of Gr-1+ CD11b+ Cells
CD45+ Gr-1+ CD11b+ cells were sorted (>98%) from spleens and pancreata of
tumor-bearing KPCmice using a BD FACSAria flow cytometer. Cytospin prep-
arations were stainedwith Diff-Quickmodified Giemsa reagent (Polysciences).
Isolation of Gr-1+ CD11b+ Cells and Functional T Cell
Suppression Assay
Gr-1+ CD11b+ cells were isolated from the spleen and pancreas of KPC mice
by cell sorting or by high-gradient magnetic cell separation (MACS; Miltenyi
Biotec, Bergisch-Gladbach, Germany). For magnetic separation, single cell
suspensions were incubated with Gr-1 biotinylated mAb (RB6-8C5) followed
by anti-biotin mAb coupled to magnetic beads (Miltenyi Biotec) and sorted
using MS MACS columns and the MidiMACS system (Miltenyi Biotec)
(>90%Gr-1+ CD11b+ cells by flow cytometry). Antigen-specific and polyclonal
suppression of CD8+ T cells was evaluated in a co-culture assay in which sple-
nocytes from either OT-1 transgenic mice (antigen-specific assay) or normal
mice (polyclonal assay) were seeded in triplicates in 96-well round bottom
plates (83 105/well). Splenocytes were cultured in the presence of increasing
ratios of Gr-1+ CD11b+ cells and stimulated with either cognate antigen, OVA-
derived peptide SIINFEKL (1 mg/ml; New England Peptide) (antigen-specific
assay), or anti-CD3 (0.5 mg/ml; BD Biosciences; 145-2C11) and anti-CD28
(1 mg/ml; BDBiosciences; 37.51) (polyclonal assay). On day 3 of the co-culture,
cells were pulsed with 3[H]-thymidine (1 mCi per well; Amersham Biosciences)
and 18 hr later 3[H]-thymidine incorporation was assessed. In some experi-
ments, the OT-1 splenocytes were labeled with CFSE. OT-1 CD8+ T cells
were evaluated on day 3 by flow cytometry for CFSE dilution.
CFSE Labeling of Mouse Cells
Cells were resuspended at 10-20x106 per mL in a minimum volume of 500 ml
PBS and incubated with CFSE (0.5 mM) at RT for 8 min with constant swirling.
The reaction was then quenched with media containing 10% FCS.
Arginase Production
Gr-1+ CD11b+ cells (106) were isolated, resuspended in 50 ml lysis buffer (0.1%
Triton X-100 with 100 mg/ml Pepstatin A, Aprotinin, and Antipain), and shaken
for 30min at 37C. Following lysis, 50 ml of 50 mM Tris-HCl / 10 mMMnCl2 was
added and the mixture was heated for 10 min at 56C. The lysate was incu-
bated with 100 ml of 0.5 M L-arginine for 120 min at 37C. The reaction was
stopped with 800 ml of H2SO4 (96%) / H3PO4 (85%) / H20 (1:3:7 by volume).
Subsequently, 40 ml of 9% (by weight) a-isonitrosopropiophenone (ISPF) in
100% ethanol was added, followed by heating at 95C for 30 min. After
10min in the dark, urea concentration wasmeasured at 540 nm and compared
to a standard curve generated by serial dilution of 750 mg/ml urea. Arginase
activity (units) was determined by the amount of urea (mg) formed per minute.
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Nitric oxide production by Gr-1+ CD11b+ cells was evaluated in culture super-
natant from the OT-1 T cell suppression assay using the Griess Reagent
System (Promega). Equal volumes of supernatant (40 ml) and 1% sulfanilamide
in 5%phosphoric acid were incubated at RT for 10min, followed by addition of
0.1% N-1-naphthylethylenediamine dihydrochloride in water. After 10 min at
RT, absorbance at 550 nm was measured. Nitrite concentrations were deter-
mined by comparing absorbance values to a standard curve generated by
serial dilution of 0.1 mM sodium nitrite.
BrdU Labeling and Analysis
c-kit+ lineage cells on day 4 of culture were labeled with BrdU (BD Biosci-
ences; 10 mM) for 2 hr at 37C and prepared for flow cytometric analysis
according to the FITC BrdU Flow Kit (BD Biosciences).
Cell Lines
PDA cell lines from KPC mice were derived by from single cell suspensions of
PDA tissue. Dissociated cells were plated in a 6-well dish with serum free
DMEM. After 2 weeks, media was changed to DMEM + 10% FCS. After 3–6
passages, cells were used in experiments. Cell lines established from PDA
tumors of KPC mice with confirmed genotypes were injected into normal
mice to confirm tumorigenicity. At necropsy, transplanted tumors were
inspected pathologically by H&E staining and invasive carcinoma was
confirmed.
Fresh Tumor Supernatant Collection
Tumors were excised, washed in PBS, weighed, and minced into small frag-
ments with sterile scissors. Tissue supernatant was harvested by adding
400 ml complete media and compressing tumor fragments with the plunger
of a 3 ml syringe. The tumor tissue solution was centrifuged at 13,000 rpm 3
10 min, and the supernatant carefully collected.
Cytokine Analysis
Cytometric bead array (BD Biosciences) and ELISA (R&D systems) were used
to quantify cytokines in supernatant from PDA lines and wild-type pancreatic
ductal cell lines cultured in DMEM + 10% FCS and in supernatant harvested
from freshly isolated KPC tumors. For both methods, quantification of cyto-
kines was determined by reference to recombinant murine standards.
Pancreas Cell Sorting and Transcriptional Analysis
Single pancreas cells from tumor-bearingKrasG12D; p53fl/+;Pdx1-Cre; RosaYFP
mice and non-tumor-bearing Pdx1-Cre; RosaYFP control mice were sorted
based on YFP fluorescence into tubes with chilled RLT buffer (QIAGEN). The
sorted YFP+ and YFP populations are referred to as pancreatic epithelial
and stromal compartments, respectively. RNA was extracted from samples
using the RNEasy kit (QIAGEN). First strand cDNA was synthesized using
SuperScript III (Invitrogen). qPCR was performed using Taqman probes for
GAPDH and GM-CSF (Applied Biosystems). Relative expression was deter-
mined after adjusting for GAPDH.
shRNA Knockdown of GM-CSF in PDA-1 Cells
GIPZ lentiviral shRNAmir targeting GM-CSF (Clone ID: V2LMM_64126) and
GIPZ nonsilencing control viral particles (Catalog # RHS4348) were purchased
from OpenBiosystems. PDA-1 cells were infected with high-titer concentrated
lentiviral suspensions and selected with 10 mg/ml Puromycin. GFP-positive
single cells were sorted using a MoFlo cell sorter and clonal PDA-1 cell lines
were derived. In vitro growth kinetics for shGM-CSF PDA-1 cells or mock
PDA-1 cells did not differ from the parental PDA-1 cell line.
Short-Term PDA Implantation Studies
PDA-1 tumor cells (106) were injected subcutaneously with anti-GM-CSFmAb
(BioLegend; 250 mg) or purified rat IgG2a (BioXcell; 250 mg) imbedded as plugs
with matrigel matrix (Collaborative Biomedical Products) into the flanks of
normal control mice for 6 days. For GM-CSF knockdown studies, mock
PDA-1 cells (106) or shGM-CSF PDA-1 cells (106) were injected subcutane-
ously with matrigel matrix for 6 days. In some experiments, tumor cells were
lethally gamma-irradiated (10 Gy) prior to implantation. For depletion of
CD8+ T cells or Gr-1+ cells, anti-CD8 mAb (BioXcell; 200 mg), anti-Gr-1 mAb(BioXcell; 500 mg), or as a control purified isotype control rat IgG2b (BioXcell;
200 mg) was injected intraperitoneally on days 1, 0, 1, and 3 with respect
to tumor cell inoculation.
Immunohistochemistry and Histopathology
Immunohistochemistry and histopathology were performed on frozen tissue
sections. Sections were fixed in 3% formaldehyde for analysis of CD45 (BD
Biosciences; 3-F11; 1:50) and Gr-1 (BioXCell; RB6-8C5; 15 mg/ml). Endoge-
nous peroxidases were quenched in 0.3% H2O2 in water for 10 min. Sections
were blocked with 10% goat serum in PBS + 0.1% Tween-20 for 30 min
followed by labeling with primary antibody overnight at 4C. Sections
were washed and incubatedwith goat anti-rat biotinylated secondary antibody
(BD Biosciences; 1:200) for 1 hr at RT. Remaining steps were performed
using Vectastain ABC kits (Vector Labs). Slides were counterstained with
hematoxylin.
Human surgical material was obtained after informed consent using an Insti-
tutional Review Board approved protocol. Formalin-fixed paraffin-embedded
tissues were sectioned for immunohistochemistry. After rehydration, sections
were incubated in 1% hydrogen peroxide/methanol then with 10 mM sodium
citrate/0.05% Tween-20 (pH 6.0) in a microwave oven for antigen retrieval.
Sections were then blocked with 10% serum/1% BSA/0.5% Tween-20 for
1 hr at RT, then incubated with rabbit anti-GM-CSF (Novus Biologicals) over-
night at 4C. Secondary antibody was biotinylated goat anti-rabbit IgG (Vector
Laboratories).
Immunofluorescence
Immunofluorescence was performed on frozen tissue sections. Section were
fixed in 3% formaldehyde for analysis of CD45 (BD Biosciences; 3-F11;
1:50) or 20C methanol for analysis of Gr-1 (BioXCell; RB6-8C5; 15 mg/ml)
and CD8 (BioXCell; 2.43; 15 mg/ml). Sections were blocked with 10% goat
serum in PBS + 0.1% Tween-20 for 30 min followed by labeling with primary
antibody overnight at 4C. Sections were washed and incubated with Alexa
Fluor 568 goat anti-rat secondary antibody (Invitrogen; 1:500) along with
DAPI (Invitrogen; 1:1000) for 1 hr at RT protected from the light. Sections
were mounted with Aqua-Poly/Mount (Polysciences).
CD8+ T Cell IFN-g/CD107a Analysis
Single cell suspensions of matrigel tumor plugs were mixed with anti-CD107a
FITC (1:100) and plated in a 96-well round bottom plate with GolgiStop protein
transport inhibitor (containing monensin) (BD Biosciences) and complete
media or media containing anti-CD3 (0.5 mg/ml) and anti-CD28 (1 mg/ml) as
a positive control. Cells were incubated at 37C for 5 hr, then were washed
and stained for surface molecules. Cells were fixed and permeabilized
(eBiosciences) followed by intracellular cytokine staining with anti-IFN-g PE
(1:50; BD Biosciences) prepared in permeabilization buffer for 20 min at 4C.
Cells were washed and analyzed on a FACSCanto flow cytometer (BD Biosci-
ences) for IFN-g and CD107a expression on CD45+ CD8+ CD11b CD11c
CD4 CD19 cells.
Statistical Analyses
All statistical analyses were determined by Student’s t test using GraphPad
Prism software.
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